This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Combined immunodeficiency, unspecified중증복합면역결핍장애 NOS

ICD-10: D81.9 | Synonyms: SCID NOS, severe combined immunodeficiency, unspecified, Severe combined immunodeficiency unspecified

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Discovery of severe combined immunodeficiency

Severe Combined Immunodeficiency (SCID) became known in 1958 when Glanzmann and Riniker in Switzerland first described a syndrome of recurrent infections and infant death. These early cases were called 'Swiss-type agammaglobulinemia', and it was later shown that defects of both T cells and B cells were involved.

Identification of ADA deficiency and X-linked SCID

In 1972, Giblett et al. discovered that adenosine deaminase (ADA) deficiency was the cause in some SCID patients, which became the starting point for elucidating the biochemical mechanisms of immunodeficiency. In 1993, Noguchi et al. showed that X-linked SCID (SCID-X1) is caused by mutations in the IL2RG gene, and many other SCID-related genes, including JAK3, IL7R, RAG1, RAG2, and DCLRE1C, were subsequently identified.

Meaning and current status of ICD-10 D81.9

ICD-10 code D81.9 (combined immunodeficiency, unspecified) applies to subtypes that show the clinical syndrome of severe combined immunodeficiency with defects in both T-cell and B-cell function but whose molecular genetic cause has not been fully identified or that lack a specific code in the classification. With advances in next-generation sequencing (NGS) technology, the proportion of patients in this category is gradually decreasing.

History in Korea

In Korea, diagnosed cases of SCID began to be reported from the 1980s~1990s along with the development of pediatric immunology. Rare immune disease centers at Seoul National University Children's Hospital, Samsung Medical Center, Asan Medical Center, and others play a central role in managing SCID patients in Korea.

2. Causes

Diverse genetic causes

Unspecified combined immunodeficiency classified as D81.9 can be caused by various gene mutations that severely impair the development or function of both T cells and B cells. Major causative genes include IL7R, JAK3, IL2RG, ADA, DCLRE1C (Artemis), RAG1, RAG2, PRKDC, LIG4, NHEJ1, and others.

Unidentified causes

Even with current technology, the molecular cause is not clearly identified in about 10~20% of SCID patients. In such cases, code D81.9 applies. This proportion is gradually decreasing with the discovery of new gene mutations.

Common pathogenic mechanism

Regardless of cause, all combined immunodeficiencies share a common pathology of impaired development or function of T lymphocytes and B lymphocytes and loss of both cell-mediated and humoral immunity.

3. Genetics

Diversity of inheritance patterns

SCID is divided into X-linked recessive (IL2RG-related, about 40% of all SCID) and autosomal recessive (related to ADA, JAK3, IL7R, RAG1/2, etc., about 60%). D81.9 also includes cases in which a specific inheritance pattern has not been established.

Phenotypes by major gene

GeneLocationMode of inheritanceImmunophenotype
IL2RGXq13.1X-linked recessiveT⁻B⁺NK⁻
JAK319p13.1Autosomal recessiveT⁻B⁺NK⁻
IL7R5p13Autosomal recessiveT⁻B⁺NK⁺
ADA20q13.11Autosomal recessiveT⁻B⁻NK⁻
RAG1/RAG211p13Autosomal recessiveT⁻B⁻NK⁺
DCLRE1C10p13Autosomal recessiveT⁻B⁻NK⁺

Novel causative genes

With advances in whole-genome sequencing (WGS) technology, various novel causative genes such as CARMIL2, CARD11, PIK3CD, and PIK3R1 continue to be discovered.

4. General epidemiology

Worldwide prevalence

The overall incidence of SCID is estimated at about 1 per 50,000~100,000 births. Since the recent introduction of newborn TREC screening, some countries have reported a level of 1 per 58,000 births. D81.9 (unspecified) corresponds to the proportion of SCID patients whose genetic cause is unidentified, accounting for about 10~20% of all SCID.

Status in Korea

Systematic statistics on SCID incidence in Korea are lacking, but it is estimated that no more than a few dozen patients are diagnosed annually. According to Health Insurance Review & Assessment Service (HIRA) data, patients registered under D81-series diagnosis codes number about 200~300 as of the 2020s. Discussions on introducing TREC-based newborn screening are also actively under way in Korea.

Special populations

The frequency of autosomal recessive SCID is higher in populations with a high frequency of consanguineous marriage and in certain ethnic groups (Saudi Arabia, Turkey, Pakistan, etc.). With the increase in multicultural families in Korea, patients with such genetic backgrounds may increase.

5. Pathophysiology

Impaired cytokine signaling

In IL2RG or JAK3 mutations, signaling of all cytokines that use the common gamma chain (γc), such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, is blocked. As a result, T-cell and NK-cell development is severely impaired, and B cells are formed but are nonfunctional.

Impaired V(D)J recombination

Mutations in RAG1/RAG2, Artemis, LIG4, NHEJ1, and others make V(D)J recombination of T-cell receptor and B-cell receptor genes impossible, so no functional T cells or B cells are produced at all.

Metabolic toxicity

In ADA deficiency, adenosine and deoxyadenosine accumulate and are directly cytotoxic to lymphocytes. This affects T cells, B cells, and NK cells alike, producing the T⁻B⁻NK⁻ phenotype.

Impaired thymic development

In some genotypes, impaired development of the thymic epithelium itself is involved, and thymic hypoplasia appears as part of the combined immunodeficiency. Without a functional thymus, T-cell maturation is fundamentally impossible.

6. Symptoms

Features of presentation in infancy

Combined immunodeficiency almost always presents within 3~6 months after birth. Infections increase sharply from the time maternally transferred antibodies (maternal IgG) disappear. Because there are no symptoms right after birth, early diagnosis is often difficult.

Recurrent opportunistic infections

Without treatment, opportunistic infections recur, such as Candida stomatitis·esophagitis, Pneumocystis jirovecii pneumonia (PCP), viral pneumonia (CMV, adenovirus, RSV), and persistent rotavirus infection. Fatal infections occur even with pathogens that are usually mild.

Other symptoms

Persistent diarrhea, malabsorption, and failure to thrive are common. Disseminated BCG infection can occur after BCG vaccination, so ulceration at the BCG vaccination site or lymphadenopathy can be a diagnostic clue. Transfusion-associated graft-versus-host disease (TA-GvHD) can occur after transfusion from blood relatives.

7. Signs

Physical examination findings

In infants, nonpalpable lymph nodes and poorly developed tonsils are characteristic. Chest retractions due to chronic pneumonia, reduced oxygen saturation, and oral thrush due to Candida are found on physical examination. Underweight and short stature due to failure to thrive appear.

Laboratory findings

Peripheral blood lymphopenia (absolute lymphocyte count below 1,500/μL) is characteristic. On lymphocyte subset analysis, marked reduction or absence of T cells (CD3+) is the key finding, while B cells and NK cells vary by subtype. On immunoglobulin quantification, IgG, IgA, and IgM are all reduced or at unmeasurable levels. T-cell function testing (PHA proliferation response) shows a markedly reduced or absent response.

Imaging findings

Absence of the thymic shadow on chest X-ray is an important sign. Chest CT can confirm the absence of thymic tissue formation. Bilateral interstitial lung opacities are characteristic of Pneumocystis pneumonia.

8. Screening

TREC-based newborn screening

T-cell receptor excision circle (TREC) testing is currently the most effective newborn screening method for SCID. Circular DNA fragments (TRECs) generated as T cells mature in the thymus are quantified by PCR from newborn dried blood spots to detect impaired T-cell development. In the United States, all states have performed TREC newborn screening since 2018.

Status in Korea

In Korea, TREC-based newborn screening is not included in the standard program but is being performed on a pilot basis at some tertiary hospitals. Korean rare immune disease expert groups and the Korean Society of Pediatric Allergy and Immunology are actively pushing for the introduction of TREC newborn screening.

Criteria for clinical suspicion

In infants under 6 months of age, an absolute lymphocyte count below 3,000/μL strongly suggests SCID, and further immunological testing is performed. Recurrent opportunistic infections, disseminated infection after BCG vaccination, or absence of the thymic shadow call for immediate immunological evaluation.

9. Diagnosis

Immunological testing

Complete blood count and lymphocyte subset analysis (CD3, CD4, CD8, CD19, CD56, CD16) are the first-line tests. T-cell function testing (mitogen proliferation response), immunoglobulin quantification (IgG, IgA, IgM, IgE), and TREC/KREC quantification are added. SCID diagnostic criteria: CD3+ T-cell count below 300/μL and a proliferative response to PHA stimulation below 10% of normal controls.

Genetic testing

Primary immunodeficiency NGS panel testing (covering 50~300 genes) is standard for molecular confirmation. If the panel is not diagnostic, whole-exome sequencing (WES) or whole-genome sequencing (WGS) is performed. Parent trio analysis is recommended to address the possibility of de novo mutations.

Functional testing

ADA activity measurement (in red blood cells), JAK-STAT signaling function testing, and T-cell proliferation assays are used to diagnose specific subtypes. Thymic imaging (ultrasound or CT) is used to assess thymic formation.

10. Treatment

Hematopoietic stem cell transplantation (HSCT)

The curative treatment for SCID is hematopoietic stem cell transplantation (HSCT). The earlier it is performed (ideally within 3 months of birth, before infection), the higher the survival rate. Matched sibling donor (MSD) transplantation is best, but HLA-matched unrelated donor (MUD), haploidentical, and cord blood transplantation are also used.

Treatment specific to ADA deficiency

In ADA-SCID, polyethylene glycol-adenosine deaminase (PEG-ADA) enzyme replacement therapy is used before transplantation and when transplantation is not possible. A lentiviral vector-based ADA gene therapy (Strimvelis) has been approved in Europe, and a related next-generation gene therapy has also been licensed in the United States.

Infection prevention and supportive care

PCP prophylaxis (TMP-SMX), antifungals (fluconazole), antivirals (acyclovir), and regular IVIG are essential before and after transplantation. Only irradiated blood products are used to prevent TA-GvHD, and live vaccines are absolutely contraindicated.

Gene therapy

Clinical trials of lentiviral and CRISPR-based gene therapies for SCID-X1 (IL2RG), ADA-SCID, and RAG1/2-related SCID are under way worldwide.

11. Prognosis

Prognosis without transplantation

Without treatment, most SCID patients die of recurrent infections and multiple organ failure within 1~2 years of birth.

Prognosis after transplantation

With early transplantation before infection occurs (within 3 months of birth), 5-year survival reaches 90% or higher. Survival decreases markedly after infection has occurred or when transplantation is delayed. 5-year survival is about 80~90% with matched sibling donor transplantation, about 70~80% with unrelated transplantation, and about 50~70% with haploidentical transplantation.

Outcomes of gene therapy

In gene therapy for ADA-SCID, follow-up of more than 10 years has confirmed recovery of immune function in over 80%. Similar outcomes are being reported for lentiviral gene therapy in SCID-X1.

12. Prevention

Early introduction of newborn screening

Introduction of TREC-based newborn screening is the most important public health measure related to SCID prevention. Early diagnosis can prevent infection before transplantation and maximize transplant outcomes. Nationwide introduction of TREC newborn screening in Korea is urgently needed.

Genetic counseling and prenatal diagnosis

When there is an affected sibling or carrier parents have been identified, prenatal genetic testing by CVS or amniocentesis is performed in subsequent pregnancies. Preimplantation genetic testing by PGT-M is also possible.

Preventive management of affected patients

Absolute contraindication of live vaccines, use of irradiated blood products only, regular IVIG, prophylactic antibiotics·antifungals, and minimizing exposure to sources of infection are the key preventive measures. A protective isolation environment must be maintained until transplantation.

13. References

  1. Glanzmann E, Riniker P. Essentielle Lymphocytophthise. Ann Paediatr. 1950;175:1-32.
  2. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972;2(7786):1067-1069.
  3. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993;73(1):147-157.
  4. Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014;371(5):434-446.
  5. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-672.
  6. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729-738.
  7. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Sci Transl Med. 2011;3(97):97ra80.
  8. Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification. Front Immunol. 2014;5:162.
  9. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S182-194.
  10. Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers. 2015;1:15061.
  11. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625-655.
  12. Heimall J, Puck J, Buckley R, et al. Current knowledge and priorities for future research in late effects after hematopoietic stem cell transplantation for severe combined immunodeficiency patients. Biol Blood Marrow Transplant. 2017;23(3):379-387.